Zobrazeno 1 - 10
of 23
pro vyhledávání: '"CS Vallejos"'
Autor:
CS Vallejos, WR Cruz, Luis Mas, Silvia P. Neciosup, Joseph A. Pinto, R. G. Velarde, Henry L. Gomez, Carlos E. Vigil, JF Suazo
Publikováno v:
Cancer Research. 70:P4-09
Background: TNBC is characterized by the lack of hormonal receptors and HER2 expression and occurs most frequently in Black and Hispanic than in Caucasian population. We compare clinicopathological and outcome variables between TNBC and non-TNBC Hisp
Autor:
WR Cruz, Silvia P. Neciosup, Henry L. Gomez, JF Suazo, Joseph A. Pinto, Carlos E. Vigil, F. F. Doimi, MJ Falla, Luis Mas, CS Vallejos
Publikováno v:
Cancer Research. 70:P1-14
Background: Phenotype plays an important role in BC biology and outcome. We evaluated the characteristics and outcomes of clinical stages I-III BC patients with recurrence according to the IHC phenotype: ER or PR+/HER2-; HER2+ (regardless the ER and
Autor:
Silvia P. Neciosup, F. F. Doimi, Ce. Vigil, M. J. Marcelo, Joseph A. Pinto, CS Vallejos, JF Suazo, R. G. Velarde, Jose M. Cotrina, Henry L. Gomez
Publikováno v:
Cancer Research. 70:P4-09
Background: Breast cancer (BC) has a worse prognosis in young than in older women; there is a lack of a standard definition of ages included in definition of young women; however ≥35 years old (yo) is frequently used. We analyzed pts according to t
Autor:
Joseph A. Pinto, Henry L. Gomez, Luis J. Schwarz, Silvia P. Neciosup, Jeannie Navarro Vásquez, CS Vallejos, G. Ferreyros, Tatiana Vidaurre
Publikováno v:
Cancer Research. 72:P6-07
Background: There are signs and symptoms detected at CNS relapse in breast cancer patients that could be identified as a poor prognosis feature of the disease. Objectives: To describe the commonest signs and symptoms at CNS relapse and its relation w
Publikováno v:
Cancer Research. 72:P6-07
Objective: We evaluated breast cancer immunophenotype and variables measured at CNS-relapse as prognostic factors in a cohort of Hispanic patients. Methods: We reviewed data from 2602 breast cancer women in stages I-III diagnosed between 2000 and 200
Autor:
Silvia P. Neciosup, WR Cruz, Tatiana Vidaurre, Henry L. Gomez, Carlos E. Vigil, JF Suazo, CS Vallejos, Julio Abugattas, R. G. Velarde
Publikováno v:
Cancer Research. 69:6052-6052
Background: HER2 expression is widely measured on tumor tissue from breast cancer patients since it gives prognostic and predictive information. Data suggest that breast cancer growth is regulated by the coordinated action of the estrogen receptor (E
Autor:
Rosillon D; GSK, Wavre, Belgium., Baril L; GSK, Wavre, Belgium., Del Rosario-Raymundo MR; Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, The Philippines., Wheeler CM; University of New Mexico Health Sciences Center, Albuquerque, New Mexico., Skinner SR; Vaccines Trials Group, Telethon Kids Institute, Perth, Western Australia, Australia.; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, New South Wales, Australia., Garland SM; The Royal Women's Hospital, The Royal Children's Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia., Salmeron J; Instituto Mexicano del Seguro Social, Morelos, Mexico., Lazcano-Ponce E; National Institute of Public Health, Cuernavaca, Mexico., Vallejos CS; Departamento de Oncología Médica, Oncosalud-AUNA, Lima, Peru., Stoney T; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., Ter Harmsel B; Department of Gynecology, Roosevelt Kliniek, Leiden, Delft, The Netherlands., Lim TYK; KK Hospital, Singapore City, Singapore., Quek SC; ASC Clinic for Women, Gleneagles Hospital, Singapore City, Singapore., Minkina G; City Clinical Hospital, Moscow, Russia., McNeil SA; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada., Bouchard C; Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada., Fong KL; Singapore General Hospital, Singapore City, Singapore., Money D; The Women's Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada., Ilancheran A; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore City, Singapore., Savicheva A; Laboratory of Microbiology, DO Ott Research Institute of Obstetrics, Gynaecology and Reproductology, St. Petersburg, Russia., Cruickshank M; Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, NHS Grampian, Scotland, UK., Chatterjee A; Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, South Dakota., Fiander A; Leading Safe Choices Programme, Royal College of Obstetricians and Gynaecologists, London, UK., Martens M; Reading Hospital, Pennsylvania., Bozonnat MC; 4Clinics, Paris, France., Struyf F; GSK, Wavre, Belgium., Dubin G; GSK, King of Prussia, Pennsylvania., Castellsagué X; Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.
Publikováno v:
Cancer medicine [Cancer Med] 2019 Aug; Vol. 8 (10), pp. 4938-4953. Date of Electronic Publication: 2019 Jul 05.
Autor:
Moore HCF; Cleveland Clinic Foundation, Cleveland, OH., Unger JM; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA., Phillips KA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.; Breast Cancer Trials Australia and New Zealand (BCT-ANZ), Newcastle, Australia.; International Breast Cancer Study Group (IBCSG), Bern, Switzerland., Boyle F; University of Sydney, Sydney, NSW, Australia., Hitre E; National Institute of Oncology, Budapest, Hungary., Moseley A; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA., Porter DJ; Auckland Regional Cancer and Blood Service, Auckland, New Zealand., Francis PA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.; Breast Cancer Trials Australia and New Zealand (BCT-ANZ), Newcastle, Australia.; International Breast Cancer Study Group (IBCSG), Bern, Switzerland., Goldstein LJ; Fox Chase Cancer Center, Philadelphia, PA., Gomez HL; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Vallejos CS; Oncosalud AUNA, Lima, Peru., Partridge AH; Dana Farber Cancer Institute, Boston, MA., Dakhil SR; Wichita NCORP, Wichita, KS.; Louisiana State University Health Sciences Center, New Orleans, LA., Garcia AA; Louisiana State University Health Sciences Center, New Orleans, LA., Gralow JR; Seattle Cancer Care Alliance, and University of Washington, Seattle, WA., Lombard JM; Calvary Mater Hospital, Newcastle, Australia., Forbes JF; Breast Cancer Trials Australia and New Zealand (BCT-ANZ), Newcastle, Australia.; Calvary Mater Hospital, Newcastle, Australia., Martino S; The Angeles Clinic and Research Institute, Santa Monica, CA., Barlow WE; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA., Fabian CJ; University of Kansas Cancer Center, Kansas City, KS., Minasian LM; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD., Meyskens FL; University of California at Irvine Chao Family Comprehensive Cancer Center, Orange, CA., Gelber RD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA., Hortobagyi GN; MD Anderson Cancer Center, Houston, TX., Albain KS; Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2019 Feb 01; Vol. 111 (2), pp. 210-213.
Autor:
Pinto JA; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima 15036, Peru., Pinillos L; Departamento de Radioterapia, Oncosalud-AUNA, Lima 15036, Peru., Villarreal-Garza C; Departamento de Investigación y de Tumores Mamarios, Instituto Nacional de Cancerología, Mexico City 14080, Mexico., Morante Z; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima 15036, Peru.; Departamento de Oncología Médica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru., Villarán MV; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima 15036, Peru., Mejía G; Departamento de Oncología Médica, Hospital Clínico Viedma, Cochabamba 00725, Bolivia., Caglevic C; Medical Oncology Department, Clinica Alemana, Santiago 5951, Chile.; Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 700, Chile., Aguilar A; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima 15036, Peru., Fajardo W; Departamento de Medicina Especializada, Hospital Nacional Dos de Mayo, Lima 15003, Peru., Usuga F; Grupo de Radioterapia Oncológica, Instituto Nacional de Cancerología, Bogotá 9-85, Colombia., Carrasco M; Departamento de Oncología, Hospital Santa Rosa, Lima 95405, Peru.; Unidad de la Mama, Oncosalud-AUNA, Lima 15036, Peru., Rebaza P; Unidad de la Mama, Oncosalud-AUNA, Lima 15036, Peru., Posada AM; Unidad de la Mama, Oncosalud-AUNA, Lima 15036, Peru., Tirado-Hurtado I; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima 15036, Peru., Flores C; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima 15036, Peru., Vallejos CS; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima 15036, Peru.
Publikováno v:
Ecancermedicalscience [Ecancermedicalscience] 2019 Jan 22; Vol. 13, pp. 897. Date of Electronic Publication: 2019 Jan 22 (Print Publication: 2019).
Autor:
Pinto JA; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru., Vallejos CS; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Raez LE; Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, Florida, USA., Mas LA; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Ruiz R; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Torres-Roman JS; Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga de Ica, Ica, Peru., Morante Z; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Araujo JM; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru., Gómez HL; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Aguilar A; Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima, Peru., Bretel D; Grupo de Estudios Clínicos Oncológicos Peruano (GECOPERU), Lima, Peru., Flores CJ; Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru., Rolfo C; Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium.
Publikováno v:
ESMO open [ESMO Open] 2018 Apr 13; Vol. 3 (3), pp. e000344. Date of Electronic Publication: 2018 Apr 13 (Print Publication: 2018).